NextCure, Inc. (NXTC): Price and Financial Metrics
NXTC Price/Volume Stats
| Current price | $1.61 | 52-week high | $2.57 |
| Prev. close | $1.60 | 52-week low | $0.98 |
| Day low | $1.55 | Volume | 101,300 |
| Day high | $1.68 | Avg. volume | 237,038 |
| 50-day MA | $1.72 | Dividend yield | N/A |
| 200-day MA | $1.45 | Market Cap | 44.92M |
NXTC Stock Price Chart Interactive Chart >
NextCure, Inc. (NXTC) Company Bio
NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
Latest NXTC News From Around the Web
Below are the latest news stories about NEXTCURE INC that investors may wish to consider to help them evaluate NXTC as an investment opportunity.
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom FishingNextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryBELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats” in JMBR Plus, a journal of the American Society for Bone and Mineral Research |
NextCure (NXTC) Down on Shelving Plans to Develop CandidateNextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same. |
NextCure Provides Year-End Clinical Pipeline UpdatesBELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline. NC410 (LAIR-2 fusion) The Phase 1b combination trial of NC410 with pembrolizumab is ongoing.Given evidence of clinical activity to date, additional patients are being added to the 100 mg cohort o |
NextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceBELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET. A live audio webcast will be available through the Investors section of |
NXTC Price Returns
| 1-mo | -15.26% |
| 3-mo | 37.61% |
| 6-mo | 54.81% |
| 1-year | 2.88% |
| 3-year | -83.05% |
| 5-year | N/A |
| YTD | 41.23% |
| 2023 | -19.15% |
| 2022 | -76.50% |
| 2021 | -44.95% |
| 2020 | -80.65% |
| 2019 | N/A |
Loading social stream, please wait...